Clinical efficacy, as measured by EULAR response rate and ACR response rate, at (A) Day 28 and (B) after a total of 4 months' treatment
| (A) | Tofacitinib 10 mg BID | Placebo |
|---|---|---|
| EULAR response, n/N (%) | ||
| Good | 1/14 (7.1%)* | 0/14 |
| Moderate | 10/14 (71.4%) | 1/14 (7.1%) |
| None | 3/14 (21.4%) | 13/14 (92.9%) |
| ACR response, n/N (%) | ||
| ACR20 | 9/15 (60.0%) | 0/14 (0) |
| ACR50 | 6/15 (40.0%) | 0/14 (0) |
| ACR70 | 1/15 (6.7%) | 0/14 (0) |
*One patient did not have ESR for calculation of EULAR responses.